RxDoctor Payments Data

Vigen Abovian, MD

Family Medicine · Glendale, CANPI 1104135391

Payments from drug & device makers

$2,581in general payments, 2019–2025

Across 53 payments — averaging $48.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$683
  • AbbVie$628
  • Galderma Laboratories, L.p.$170
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$130
  • Optinose US, Inc.$127
  • Phathom Pharmaceuticals, Inc.$126
  • plus $717 from 10 others

What the payments were for

  • Food & beverage$2,50997%
  • Education$723%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,581 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$78,581
Medicare patients
105
Services billed
966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase58$69,090
LinzessLinaclotide111$65,356
MyrbetriqMirabegron90$40,165
TradjentaLinagliptin49$29,984
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate14$29,377
EliquisApixaban39$24,289
Diclofenac Sodium44$23,683
OzempicSemaglutide22$21,113
VascepaIcosapent Ethyl54$14,062
TrulicityDulaglutide14$13,342
Repatha SureclickEvolocumab23$12,715
JardianceEmpagliflozin20$11,853
FarxigaDapagliflozin Propanediol17$9,683
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$9,367
Breo ElliptaFluticasone/Vilanterol22$8,864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$628$134,446169 claims
Astellas Pharma US IncMyrbetriq$33$40,16590 claims
PfizerEliquis$15$24,28939 claims
Lilly USA, LLCTrulicity, Humalog Mix 75-25$120$15,85532 claims
AstraZenecaFarxiga$120$9,68317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →